// App-Quantinova.ai

: Keynote-365 cohort b: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Christophe Massard

Principal Investigators

  • Peter Hammerer

  • Fernando Quevedo

  • Peter C.C. Fong

  • William R. Berry

  • Howard Gurney

  • Josep M. Piulats

  • Anthony Joshua

  • Mark David Linch

  • Michael Kolinsky

  • Emanuela Romano

  • Srikala S. Sridhar

  • Henry Jacob Conter

  • Marinela Augustin

  • Haiyan Wu

  • Charles Schloss

  • Christian Heinrich Poehlein

  • Evan Y. Yu

Medical Centers

  • Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France

  • Rechts der Isar University Hospital, Technical University of Munich, Munich, Germany

  • Academic Hospital Braunschweig, Braunschweig, Germany

  • Mayo Clinic, Rochester, MN

  • Auckland City Hospital, Auckland, New Zealand

  • Duke University College of Medicine, Durham, NC

  • Macquarie University Hospital, Sydney, Australia

  • Catalan Cancer Institute, Barcelona, Spain

  • The Kinghorn Cancer Centre, St Vincents Hospital, Sydney, Australia

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Institut Curie, Paris Cedex, France

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • University of Western Ontario, London, ON, Canada

  • Klinikum Arnsberg, Arnsberg, Germany

  • Merck & Co., Inc., Kenilworth, NJ

  • University of Washington, Seattle, WA

Locations

  • France

  • Germany

  • United States

  • New Zealand

  • Australia

  • Spain

  • United Kingdom

  • Canada

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Nephrology

  • Musculoskeletal

  • Oncology (ONC)

Disease

  • Metastatic castration-resistant prostate cancer

  • Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Pembrolizumab

  • Enzalutamide

  • CB-7598

  • Prednisone

  • Docetaxel

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • NCT02861573

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved